This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e19. Learning Objective: Upon completion of this CME activity successful learners will be able to: ascertain the evidence on comparative diagnostic performance of different noninvasive imaging modalities for detection of cirrhosis, and performance of different vibration-controlled transient elastography-based liver stiffness cut-offs for detection of cirrhosis and clinically significant portal hypertension in patients with chronic liver diseases, in different clinical and practice settings.
Chronic liver diseases (CLDs), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liver diseases (NAFLD); and alcoholic liver disease, are a leading cause of morbidity and mortality globally. Early identification of patients with cirrhosis at high risk of progression to liver-related complications may facilitate timely care and improve outcomes. With risks and misclassification associated with invasive tests, such as liver biopsy, noninvasive imaging modalities for liver fibrosis assessment have gained popularity. Therefore, the American Gastroenterological Association prioritized clinical guidelines on the role of elastography in CLDs, focusing on vibration-controlled transient elastography (VCTE) and magnetic resonance elastography (MRE). To inform these clinical guidelines, the current technical review was developed in accordance with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework for diagnostic accuracy studies. This technical review addresses focused questions related to: (1) comparative diagnostic performance of VCTE and MRE relative to nonproprietary, serum-based fibrosis markers for detection of cirrhosis in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD, and alcoholic liver diseases; (2) performance of specific VCTE-defined liver stiffness cutoffs as a test replacement strategy (to replace liver biopsy) in making key decisions in the management of patients with CLDs; and (3) performance of specific VCTE-defined liver stiffness cutoffs as a triage test to identify patients with low likelihood of harboring high-risk esophageal varices (EVs) or having clinically significant portal hypertension (for presurgical risk stratification). This technical review does not address performance of other noninvasive modalities for assessing fibrosis (eg, acoustic radiation force pulse imaging or shear wave elastography) or steatosis (controlled attenuation parameter or magnetic resonance imagingLestimated proton density fat fraction).
Keywords: Fibrosis; Noninvasive Imaging; Chronic Liver Diseases; Guidelines. G lobally >1.75 million deaths are attributed to chronic liver diseases (CLDs), which are an important source of health and economic burdens. 1 In the United States, nearly 150,000 people are diagnosed with CLDs annually (of which 20% are diagnosed with cirrhosis), and 36,000 patients die of CLDs, primarily attributable to complications of decompensated cirrhosis and/or hepatocellular cancer (HCC). 2, 3 Annually, these generate approximately 5.9 million CLD-related ambulatory care visits and 759,000 CLD-related hospitalizations, with health care costs exceeding $1.5 billion. 3 HCC is the second leading cause of cancer-related death worldwide, and most patients with HCC will have underlying CLDs. 4 Globally, it is estimated that >185 million and 248 million people may be living with chronic HCV infection and chronic HBV infection, respectively; corresponding rates in the United States are approximately 4.7 million and 2 million, respectively.
5À7
NAFLD is a rapidly increasing cause of CLDs, with an estimated 13.5%À31.8% affected globally and 24.1% of adults in North America. 8 The burden of alcoholic liver disease is more difficult to determine, but one report estimated that alcohol-attributable liver cirrhosis was responsible for 493,300 deaths globally in 2010. 9 Early identification of patients at high risk for progression to decompensated cirrhosis can help direct high-value care and decrease the morbidity and mortality attributed to CLDs.
One of the key determinants of progression to CLD-related complications is degree of liver fibrosis, and is often factored in making treatment and surveillance decisions (for HCC and/or esophageal variceal screening). Historically, liver biopsy has been the gold standard for diagnosis and staging of fibrosis, in addition to its role in identifying etiology of abnormal liver enzymes and assessing degree of inflammation. However, this procedure has several limitations. It is invasive and associated with an estimated morbidity (including severe pain) and mortality rate of 3% and 0.01%, respectively; in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis trial, serious adverse events occurred in 29 of the 2740 (1.1%) biopsies performed and included 16 (0.6%) bleeding cases. 10, 11 Liver biopsy is prone to sampling error resulting in misclassification of fibrosis stage in up to 25% of cases, and there is also considerable intra-and interobserver variability in interpretation of histology, especially at lower stages of fibrosis.
12
To overcome these limitations and inconvenience of an invasive test, noninvasive serum-and imaging-based methods of staging fibrosis have been developed. Although several proprietary and nonproprietary serum-based markers have been developed, they are nonspecific for the liver and may have inferior performance characteristics to imaging-based tests. 13 Among imaging tests, ultrasound-based VCTE has been studied most extensively and validated with high intraand inter-observer reproducibility, and can be performed quickly, potentially at point of care. 14 In this technique, a piston vibrator placed in the intercostal space generates a shear wave, and then the velocity is measured in a region 25À65 mm below the skin surface with the standard adult Mprobe and 35À75 mm with the XL probe for larger patients. The unit of measurement is kilopascals (kPa), and the device readings range from 2.5 to 75 kPa.
With recent recommendations for universal screening for HCV, availability of highly effective but expensive newer direct-acting agents against HCV, and rising prevalence of NAFLD, an increasing number of patients are seeking evaluation for CLDs, and fibrosis staging through noninvasive means has become increasingly important and appealing for physicians. 15, 16 Patients also have a strong preference for VCTE over liver biopsy. In a Canadian survey of 422 patients, of whom 205 had undergone liver biopsy, approximately 95% patients preferred VCTE over liver biopsy, with the majority reporting no discomfort (84%), no feelings of anxiety (78%), short test duration and short time to result. 17 In its recent guidelines, the European Association for the Study of Liver Diseases and the Latin American Association for the Study of the Liver have recommended VCTE as a validated noninvasive standard for assessment of liver fibrosis, in patients with HCV and HBV, with >90% negative predictive value in ruling out cirrhosis. 18 However, these guidelines offer limited guidance on the diagnostic performance of specific cutoffs of VCTE-identified liver stiffness, in clinical contexts of high-and low-risk populations of patients with CLD, and its potential impact on downstream patient-important outcomes. Identifying specific cutoffs for liver stiffness corresponding to cirrhosis and advanced fibrosis could guide management decisions, including treatment for HCV and HBV and triage for preventive cirrhosis care. Therefore, the American Gastroenterological Association prioritized this topic for generation of clinical guidelines.
Objectives of This Review
This technical review addresses focused clinical questions on the diagnostic performance of VCTE (and MRE) in patients with HCV, HBV, NAFLD, and alcoholic liver disease, focusing specifically on: (1) overall performance relative to nonproprietary, serum-based fibrosis markers and (2) implications of specific liver stiffness cutoffs on downstream patientimportant outcomes. Additionally, in this review we sought to evaluate the performance of specific liver stiffness cutoffs to assess portal hypertension to triage patients with compensated cirrhosis with low likelihood of high-risk EVs, as well as its role in presurgical risk stratification of patients with CLD. 19 This review does not address the performance and utility of other noninvasive imaging modalities, such as acoustic radiation force pulse imaging or shear wave elastography. Based on feedback during the public comment period, the technical review was updated with 2 additional questions on the comparative performance of VCTE and MRE in detection of cirrhosis in patients with HCV and NAFLD.
Methods

Formulation of Clinical Questions
The participants (including SS, AJM, DTD, and YFY) for this technical review were selected by the American Gastroenterological Association Clinical Guidelines Committee based on their clinical content and guidelines methodological expertise and went through a thorough vetting process for potential conflicts of interest. Through an iterative process, the participants developed focused clinical questions deemed relevant for clinical practice that the guideline would address and that related to the diagnostic performance and utility of VCTE in 5 different populations: adults with HCV, HBV, NAFLD, chronic alcoholic liver disease, and CLD suspected to have portal hypertension. From these focused questions, well-defined statements in terms of patients, intervention, comparator, and outcome (PICO) were defined, and these formed the framework for formulating the study inclusion and exclusion criteria and guided the literature search. The American Gastroenterological Association Governing Board approved the final set of questions and statements. The focused and PICO questions are shown in Table 1 . Two questions on the role of MRE on detection of cirrhosis were added after the public comment period.
There were 2 broad themes for our focused questions. The first set of questions for each population of interest (HCV, HBV, NAFLD, and alcoholic liver diseases) were centered around the overall diagnostic performance (across a broad range of cutoffs) of VCTE in relation to commonly used, nonproprietary, noninvasive serum biomarkers of fibrosis in these conditions (aspartate aminotransferase to platelet ratio index [APRI] and fibrosis-4 index [FIB-4]) (PICO #1, 4, and 6). 13, 20 Although proprietary serum-based fibrosis markers may have slightly higher diagnostic accuracy compared with nonproprietary markers, the latter are inexpensive, easy to calculate, and widely available. 18 After the public comment period, 2 questions (PICO #11 and 12) on the comparative performance of VCTE and MRE on detection of cirrhosis in patients with HCV and NAFLD were added. The second set of focused questions were focused on identifying reliable VCTE-derived liver stiffness cutoffs to diagnose cirrhosis (PICO #2, 4, 6, and 8), or rule out advanced fibrosis (PICO #3) or rule out high-risk EVs (defined as any medium/large EV, or small varices with high-risk stigmata for bleeding) (PICO #9) or clinically significant portal hypertension (defined as presence of any EV) (PICO #10).
For PICO #1À8, VCTE was considered as a test replacement strategy for detection of cirrhosis, that is, in patients with valid results, VCTE would replace routine use of liver biopsy and limit its use to cases with inconclusive VCTE results or diagnostic equipoise. For PICO #9, VCTE was considered as a triage (screening) strategy for upper endoscopy for ruling out high-risk EVs, that is, in patients with liver stiffness below the VCTEidentified threshold, the likelihood of high-risk EVs is sufficiently low to avoid routine upper endoscopy; however, in patients with liver stiffness at or above VCTE-identified threshold, upper endoscopy is warranted to confirm diagnosis before treatment is considered. Likewise for PICO #10, VCTE was considered a triage strategy, that is, patients with liver stiffness below VCTE-identified threshold, clinically significant portal hypertension may be ruled out in risk stratification for elective, nonhepatic surgery; however, in patients with liver stiffness at or above VCTE-identified threshold, further testing (with upper endoscopy or hepatic venous pressure gradient) to evaluate clinically significant portal hypertension may be warranted before a patient is deemed high risk for elective surgery.
Search Strategy, Study Selection, Data Abstraction, and Quality Assessment Details of the search strategy, study selection, data abstraction, and risk of bias assessment is reported in the Supplementary Material.
Outcomes of Interest
For the first set of PICO statements pertaining to overall diagnostic performance of VCTE compared with other commonly used, nonproprietary, noninvasive fibrosis biomarkers or MRE, primary outcome of interest was the overall diagnostic performance (true positives [TP] For the second set of PICO statements pertaining to reliable VCTE-derived liver stiffness cutoffs to either diagnose (PICO #2, 4, 6, and 8), or rule out (PICO #3) cirrhosis or rule out high-risk EVs or any EVs (PICO #9 and 10), the preferred outcome was direct consequences on patient-important outcomes (ie, implications of TP, FP, TN, and FN results for patients, see the following section). However, none of the studies assessed these outcomes directly and, therefore, we used TP, FP, TN, and FN rates as surrogate outcomes and inferred downstream consequences on patientimportant outcomes. For questions focusing on ruling out cirrhosis, high-risk or any EVs, our outcome was minimizing rates of FN (ie, patients incorrectly being labeled as not having the condition, when they actually have the condition) with reasonable rates of TP, FP, and TN. For questions focusing on diagnosing patients with cirrhosis, our outcome was a balance of FN and FP (ie, patients incorrectly labeled as having the condition, when they actually do not have the condition). This was also estimated in different clinical scenarios, as detailed here. 3. TNs (patients correctly diagnosed as not having cirrhosis based on VCTE) would be reassured and obviate the need for invasive testing with liver biopsy, although they may need to undergo serial assessment of liver stiffness at periodic intervals.
Consequences of Diagnostic Test
4. FNs (patients incorrectly labeled as not having cirrhosis based on VCTE, when actually they have cirrhosis) would be falsely reassured, and may not receive appropriate preventive cirrhosis, may receive inappropriate treatment (shorter HCV treatment course), potentially leading to increased morbidity and mortality.
In using specific VCTE-derived liver stiffness cutoffs either as a test replacement or triage strategy, health care providers and patients need to be aware of test performance, and be comfortable with potential FN and FP rate with attending downstream consequences. Such downstream consequences of test results for each PICO statement and scenario have been discussed in detail in each evidence profile. For both test replacement and triage questions, the technical review team decided to focus on optimizing FN rate, with a reasonable FP tradeoff (depending on downstream consequences).
A premeeting questionnaire was administered to both the content experts in the technical review team and the guideline panel to determine their a priori maximal tolerable FN rate for each PICO (ie, what level of FN rate would they be willing to accept for a particular test, for their patient). As the maximally tolerable rates of FN tests for any diagnostic strategy is highly context sensitive, we devised different clinical scenarios with corresponding downstream consequences for each PICO to arrive at fully contextualized estimates of FN thresholds (see Supplementary Material).
Data Synthesis and Statistical Analysis
Details of data synthesis and statistical analysis are reported in the Supplementary Material. Specifically, for PICOs focusing on identifying reliable cutoffs, we a priori sought to identify VCTE cutoff maximizing sensitivity (to rule out cirrhosis, high-risk EVs or clinically significant portal hypertension), or maximizing specificity (to diagnose cirrhosis). However, during the data abstraction process, we recognized that variable cutoffs were not consistently reported in included studies; in addition, most studies did not prospectively study a particular cutoff, but rather retrospectively applied the cutoff corresponding to the area under the receiver operating characteristic (AUROC). Therefore, to identify reliable cutoffs, we used the most commonly reported cutoff in studies, confirmed their clinical use with content experts (and use in clinical trials which recruited patients with cirrhosis based on VCTE cutoffs), and calculated sensitivity, specificity, and positive and negative predictive values corresponding to these.
Quality of Evidence
We rated the quality of evidence using the GRADE approach for diagnostic tests and strategies. 21 In this approach, all evidence from randomized controlled trials (comparing different diagnostic tests or cutoffs of same test) and observational diagnostic accuracy studies start at high-quality, but can be rated down for any of the following factors: In the absence of direct patient-important outcomes from observational diagnostic accuracy studies, surrogate outcomes including TP, FP, TN, and FN were all rated as critical outcomes, and included in evidence profiles.
Results
Appropriate Interpretation of Transient Elastography
For optimal interpretation of VCTE, the following are required: at least 10 validated measurements and an interquartile range (reflects variations among measurements) <30% of the median value is required. 13, 14 In a prospective study of 13,369 VCTE examinations in Europe, liver stiffness measurement was unsuccessful (no valid shots could be obtained in 3% of patients), and in another 16% of patients, results were unreliable 23 ; corresponding rates in an Asian population were 2.5% unsuccessful measurement and 0.9% with unreliable liver stiffness measurement. 24 Primary factors associated with unsuccessful or unreliable measurements are: obesity (body mass index >30 kg/m 2 ), in particular, increased waist circumference, ascites, narrow inter-rib spaces, advanced age, female sex, and operator inexperience (<500 examinations).
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Besides fibrosis, factors that influence viscoelastic properties of the liver may also result in increased liver stiffness, such as the presence of severe hepatic inflammation, extrahepatic arteriovenous or biliary obstruction, and congestive heart failure. Therefore, caution should be exercised in interpreting VCTE results in patients with significant elevation in liver enzymes (aminotransferases >5Â upper limit of normal) or excessive alcohol consumption. 26À30 Recent studies have identified that nonfasting state may also significantly influence liver stiffness and, therefore, VCTE should ideally be undertaken when the patient has been fasting for at least 2 hours. 31 
Illustrative Prevalence of Cirrhosis
The diagnostic accuracy of any test in terms of rates of TP, TN, FP, and FN depends on pretest probabilities and prevalence of condition, which in turn depends on practice setting (higher prevalence of cirrhosis in referral liver clinic compared to community primary care practice), patientlevel characteristics (higher prevalence of cirrhosis in patients with concomitant viral infections like human immunodeficiency virus (HIV), obesity, diabetes, excessive alcohol use), and physician suspicion (which often encompasses practice setting and patient characteristics, including clinical history, physical examination, laboratory features). While we acknowledge that this baseline pretest probability of cirrhosis varies along a continuum of these factors, for ease of interpretation of data in day-to-day practice, we anchored the baseline prevalence of cirrhosis into 2 categories-low risk (5% prevalence of cirrhosis) and high risk (30% prevalence of cirrhosis). To illustrate this concept, patients with high risk for having prevalent cirrhosis may be asymptomatic patients with HCV, HBV, NAFLD, or alcoholic liver disease with associated obesity, diabetes mellitus, excessive alcohol use, and/or concomitant viral infections (eg, HIV), who are often seen in referral centers, and the estimated risk of cirrhosis in this population would be approximately 30%. 32À35 Patients with low risk of having prevalent cirrhosis would be those who are asymptomatic, seen by community primary care practitioners with HCV, HBV, NAFLD, or alcoholic liver disease, without clear factors associated with presence of cirrhosis, and the estimated risk of cirrhosis in this population would be approximately 5%. Using this illustrative prevalence of outcome, and sensitivity/specificity of liver stiffness cutoffs in different scenarios, positive and negative predictive value of each cutoff is summarized in Table 2 . Question 1. In adults with chronic HCV, is the overall diagnostic performance of VCTE superior to other noninvasive markers of liver fibrosis (APRI, FIB-4) for detection of cirrhosis?
Key message. In adults with chronic HCV, VCTE has superior sensitivity and specificity, and lower FP and FN rates, suggesting better diagnostic performance compared with APRI and FIB-4 for detection of cirrhosis. (Moderate quality of evidence).
Effect estimates. We used an existing well-conducted systematic review on the diagnostic performance of noninvasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with CLDs published in January 2015. 36 This systematic review included 36 studies in patients with HCV that reported on the diagnostic performance of VCTE for detection of cirrhosis using liver biopsy as a reference standard. In these studies, the liver stiffness cutoff corresponding to AUROC ranged from 9.2 to 17.3 kPa. The summary sensitivity and specificity for detection of cirrhosis across this range of cutoffs were 0.89 (95% CI, 0.84À0.92) and 0.91 (95% CI, 0.89À0.93), respectively. The evidence profiles are summarized in Tables 3 and 4 . Based on this, VCTE classified more patients correctly as having cirrhosis (TP) or not having cirrhosis (TN) compared with APRI (low cutoff), and had lower rates of misclassification (FP, FN), in both low-and high-prevalence populations; compared with FIB-4 (low cutoff), although rates of TP and FN were comparable, VCTE resulted in significantly lower FP rate.
Quality of evidence. All included studies were crosssectional diagnostic accuracy studies, required <6-month interval between performance of diagnostic test (VCTE, APRI, or FIB-4) and gold standard (liver biopsy), minimizing disease progression bias, and were generally of fair quality and not at serious risk for bias (eg, spectrum bias, disease progression bias, partial or differential verification bias, adequate blinding of outcome assessors). For comparison of diagnostic performance of VCTE with other noninvasive, serum-based fibrosis markers, rates of TP, FP, TN, and FN were directly relevant outcomes in a comparable population, and although there were limited head-to-head comparisons of VCTE and other measures, the overall body of evidence was not rated down for indirectness. Considerable heterogeneity was observed in pooled sensitivity and specificity, and there was a wide range of "ideal" cutoffs for VCTE (corresponding to AUROC), rather than prespecified cutoffs for detection of cirrhosis and, therefore, evidence was rated down for inconsistency. There was no evidence of serious imprecision, and diagnostic performance of VCTE was superior to APRI and to FIB-4 in both low-and high-risk populations, even in worst-performance scenarios (using lower limit of 95% CI for diagnostic accuracy of VCTE, and upper limit of 95% CI of APRI or FIB-4). To summarize, using the GRADE approach for diagnostic accuracy studies, the quality of evidence supporting the use of VCTE over APRI or FIB-4 for detection of cirrhosis was rated as moderate quality.
Discussion. Pretreatment assessment of fibrosis stage is important to facilitate appropriate HCV treatment decisions and determine need for additional measures for managing cirrhosis, such as HCC surveillance. 37 While nonproprietary, inexpensive, serum-based fibrosis markers like APRI and FIB-4 are readily available, their diagnostic performance was suboptimal in both low-and highprevalence scenarios, with high FP rates for detection of cirrhosis. This may result in avoidable patient anxiety and unnecessary testing and treatment. There was moderate certainty in the observation that VCTE has superior diagnostic performance in identifying cirrhosis in patients with HCV, with lower rates of misclassification of patients. We did not factor in cost-effectiveness of VCTE vs serum-based fibrosis markers, given rapidly changing prices of antiviral therapy, which may offset cost-to-benefit assessments. Effect estimates. We updated an existing systematic review, to identify a range of liver stiffness cutoffs (9.2À26.5 kPa) corresponding to optimal sensitivity and specificity for diagnosis of cirrhosis in adults with HCV. From this, we identified a narrow range of liver stiffness cutoff, 12.5 (±1) kPa, which corresponded to the most commonly observed value in included studies (17 studies, 5812 patients), and corresponding to value most commonly applied in clinical trials and practice. 38À53 Supplementary Table 1 describes the characteristics of these included studies, and Supplementary Figures 1A and B report the sensitivity and specificity of this cutoff. The performance of this cutoff in low-and high-risk populations is shown in Table 5 . In an illustrative low-risk population (5% prevalence of cirrhosis), for example, patients with HCV detected in primary care clinics during routine age-appropriate screening, using a cutoff of 12.5 (±1) kPa may misclassify 0.7% patients as not having cirrhosis (FN) and 8.6% patients as having cirrhosis (FP). In an illustrative high-risk population (30% prevalence of cirrhosis), for example, HCV patients with obesity, diabetes, excessive alcohol use, or co-infection with HIV or HBV, using a cutoff of 12.5 (±1) kPa may misclassify 4.2% as not having cirrhosis (FN) and 6.3% patients as having cirrhosis (FP).
Quality of evidence. The evidence supporting the use of this cutoff was derived from cross-sectional diagnostic accuracy studies, and there were no data on comparing different cutoffs and their effect on downstream patientimportant outcomes related to impact of cirrhosis diagnosis (or misdiagnosis). Therefore, due to use of FP and FN as surrogates for presumed downstream consequences, and because the cutoff was largely obtained from post-hoc analysis corresponding to AUROC, the overall body of evidence was rated down for indirectness. Because we selectively included only studies that identified a cutoff of 12.5 (±1) kPa, and excluded studies in which the optimal cutoff was higher or lower (in which the diagnostic performance corresponding to a cutoff of 12.5 kPa was not reported and conceivably poorer), and because considerable heterogeneity was observed in the pooled sensitivity and specificity corresponding to the identified cutoff, we rated down further for inconsistency. The diagnostic accuracy studies were generally of fair quality, and there was no serious risk of bias. In addition, there was no evidence of serious imprecision and no evidence of publication bias detected. To summarize, using the GRADE approach for using diagnostic accuracy studies for patient management, the quality of evidence supporting the use of VCTE-defined liver stiffness of !12.5 (±1) kPa for diagnosis of cirrhosis in adults with HCV was rated as low quality. Discussion. In the evaluation of patients with HCV, the stage of disease and the ability to detect cirrhosis is critical.
While fibrosis stage at which antiviral therapy should be initiated is still in flux with the introduction of highly effective but expensive direct-acting antiviral agents, patients with advanced fibrosis/compensated cirrhosis definitely require antiviral treatment to prevent progression (and potential fibrosis regression); additionally, the presence of cirrhosis may extend treatment duration with some regimens. 37 Patients with cirrhosis will also need close surveillance for complications of portal hypertension and HCC even after cure of HCV cirrhosis. 54 As mentioned earlier, in using VCTE as strategy to replace liver biopsy, health care providers and patients need to be aware of test performance and be comfortable with potential FN and FP rates with attending downstream consequences. A priori, the maximal tolerable FN rate accepted by the Technical Review and Guideline Content Expert Panel was 5%À10%, that is, the test threshold would be acceptable if <10% of patients are misclassified as not having cirrhosis. With the use of this VCTE-defined liver stiffness cutoff of 12.5 (±1) kPa, we estimated that >85% of patients would be able to avoid liver biopsy with correct classification of either having or not having cirrhosis. Importantly, we observed that with this cutoff, <1% and <5% of low-and high-risk patients, respectively, may be falsely reassured (of not having cirrhosis; FN rate), potentially may not receive adequate duration of treatment course and be at-risk of treatment failure, may not receive supportive cirrhosis and consequently, and may be at increased risk of hepatic decompensation. Additionally, with this cutoff, <10% of patients without cirrhosis, in both low-and high-risk populations, may be falsely diagnosed as having cirrhosis, and receive unnecessary tests (like surveillance for HCC) and treatment (longer antiviral therapy), and have anxiety, testing-, and treatment-related complications, and lead to excessive Supplementary Figures 2A and B report the sensitivity and specificity of this cutoff. The performance of this cutoff in low-and high-risk populations is shown in Table 6 . In an illustrative low-risk population (5% prevalence of advanced fibrosis), for example, patients with HCV who achieve SVR and have no ongoing risk factors for CLDs, using a cutoff of 9.5 (±1) kPa may misclassify 1.1% patients as not having advanced fibrosis (FN). Although the FP rate will be high with such a sensitive cutoff, the goal is to exclude significant fibrotic liver disease, and serial examinations over time may reduce this FP rate. In a high-risk population (30% prevalence of advanced fibrosis), for example, HCV patients who achieve SVR but either had cirrhosis (liver stiffness >12.5 kPa) before therapy or continue to have other risk factors for CLDs, such as obesity, diabetes, excessive alcohol use, or co-infection with HIV or HBV, using a cutoff of 9.5 (±1) kPa may misclassify 6.6% patients as not having advanced fibrosis (FN).
Quality of evidence. As with most evidence on diagnostic performance of different VCTE-derived liver stiffness cutoffs, the evidence supporting the use of this cutoff was derived from cross-sectional diagnostic accuracy studies in all patients with HCV, regardless of treatment, as opposed to studies specifically conducted in patients who achieve SVR after antiviral therapy. Additionally, there were no data on comparing different cutoffs (which were derived from post-hoc analysis corresponding to AUROC) and their effect on downstream patient-important outcomes related to impact of advanced fibrosis diagnosis (or misdiagnosis). Therefore, the overall body of evidence was rated down twice for very serious indirectness. Because we selectively included only studies that identified a cutoff of 9.5 (±1) kPa, and because considerable heterogeneity was observed in the pooled sensitivity and specificity corresponding to the identified cutoff, we rated down further for inconsistency.
There was no evidence of serious risk of bias or serious imprecision, and no evidence of publication bias was observed. To summarize, using the GRADE approach for using diagnostic accuracy studies for patient management, the quality of evidence supporting the use of VCTE-defined liver stiffness of 9.5 (±1) kPa for ruling out advanced fibrosis in adults with HCV who have achieved SVR was rated as very low quality. Discussion. With recommendations for universal screening for hepatitis C for persons born between 1945 and 1965, availability of effective antiviral therapies, tremendous numbers of patients are seeking care and being cured of HCV. For these cured patients, health care providers will need to decide whether or not they need ongoing care for their liver. This decision to discharge patients from hepatitis C care can be very meaningful to patients (who can put HCV behind them) and health care providers (to improve access to other patients to receive care for HCV). The American Association for the Study of Liver Diseases/ Infectious Diseases Society of America guidance recommends ongoing care and surveillance for complications of portal hypertension and HCC in patients with advanced fibrosis (F3À4), and no further follow-up for patients for early fibrosis (F0ÀF2). 37 The technical review team decided that it may be appropriate to discharge patients from the liver clinic if there was no evidence of advanced fibrosis on liver biopsy after SVR. However, because repeat liver biopsy after achieving SVR is not feasible or universally acceptable, VCTE-defined liver stiffness may help make decisions regarding discharging patients after treatment for HCV. The maximal tolerable predefined FN rate accepted on by the Technical Review and Guideline Content Expert Panel was 1%À5%, that is, the test threshold would be acceptable if <5% of patients are misclassified as not having advanced fibrosis and are discharged from clinic. With a cutoff of 9.5 (±1) kPa, >80% and >60% of low-risk and high-risk patients, respectively, without advanced fibrosis may be considered for discharge from a dedicated liver clinic after achieving SVR with antiviral therapy, without increased risk of patient morbidity and mortality, and decreasing health care utilization and burden. Although approximately 1% of low-risk patients may be misclassified as not having advanced fibrosis using this cutoff, approximately 7% of high-risk patients (more than the maximal tolerable FN rate) may be falsely reassured and be discharged from a dedicated liver clinic and not receive appropriate posttreatment supportive care, putting them at increased risk of hepatic morbidity and mortality. However, despite this higher rate, it is expected that most misclassifications will occur by missing some patients with stage F3 fibrosis, but a High heterogeneity, selective inclusion of studies corresponding to cutoff of 9.5 (±1) kPa. Diagnostic performance inferred from studies in the general population with HCV with or without therapy, rather than studies in patients who achieved SVR; surrogate patientimportant outcomes (FP, FN are surrogates for presumed downstream consequences on patient-important outcomes), no predetermined liver stiffness cutoff, which was determined post-hoc in individual studies, corresponding to AUROC.
likely very few or no patients with cirrhosis will be discharged. Any decision to discharge patients from a dedicated liver clinic would require consideration of other factors, such as co-existing liver diseases or ongoing abnormal liver tests. It is important to note that quality of evidence supporting this observation was very low and further research is needed in this area.
Question 4. In adults with chronic HBV, is the overall diagnostic performance of VCTE superior to other noninvasive markers of liver fibrosis (APRI, FIB-4) for detection of cirrhosis?
Key message. In adults with chronic HBV, VCTE has superior sensitivity and specificity, and lower FP and FN rates, suggesting superior diagnostic performance, as compared to APRI and FIB-4 for detection of cirrhosis.
(Low quality of evidence).
Effect estimates. We used an existing well-conducted systematic reviews on the diagnostic performance of noninvasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with CLD. 36, 62 This systematic review included 19 studies in patients with HBV, which reported on the diagnostic performance of VCTE for detection of cirrhosis using liver biopsy as a reference standard. In these studies, the liver stiffness cutoff corresponding to AUROC ranged from 9.4 to 16.0 kPa. The summary sensitivity and specificity for detection of cirrhosis across this range of cutoffs was 0.86 (95% CI, 0.79À0.91) and 0.85 (95% CI, 0.78À0.89), respectively. The evidence profiles are summarized in Tables 7 and 8 . Based on this, VCTE classified more patients correctly as compared to APRI (low cutoff) with higher rates of TP and TN, and lower rates of FP and FN, although these estimates were imprecise in worst-performance scenarios. VCTE's diagnostic performance was comparable with FIB-4 (low cutoff) for diagnosing cirrhosis, but was superior to FIB-4 in ruling out cirrhosis.
Quality of evidence. Similar to studies on diagnostic performance of VCTE in HCV, studies were not deemed to be at serious risk of bias and there was no evidence of indirectness. Considerable heterogeneity was observed and there was a wide range "ideal" cutoffs for VCTE (corresponding to AUROC), rather than prespecified cutoffs for detection of cirrhosis and, therefore, evidence was rated down for inconsistency. In the comparison of VCTE vs APRI, there was evidence of serious imprecision for both ruling in and ruling cirrhosis, whereas in the comparison of VCTE vs FIB-4, there was evidence of serious imprecision for ruling in, but not ruling out, cirrhosis in worst-performance scenarios. To summarize, using the GRADE approach for diagnostic accuracy studies, the overall quality of evidence supporting the use of VCTE over APRI or FIB-4 for detection of cirrhosis, was rated as low quality. Discussion. While several management decisions in patients with HBV are determined by host or virus-related characteristics, fibrosis assessment may be important for a subset of patients who do not meet criteria for antiviral treatment based on other characteristics. 63 However, given the risks and burden of liver biopsies, overall adherence to perform biopsy where indicated is low due to both physician-and patient-related factors 64 ; noninvasive testing may help overcome this barrier. Among noninvasive tests, we identified that low-quality evidence supported the use of VCTE over other noninvasive serum-based fibrosis markers, with lower rates of false positivity (ie, risk of falsely classifying patients as having cirrhosis and initiating lifelong therapy), although rates of FN were comparable with FIB-4.
Key message. In adults with chronic HBV, we can accurately diagnose cirrhosis (and initiate downstream management) with VCTE-defined liver stiffness of !11.0 (±1) kPa, with acceptable FP and FN rates. (Low quality of evidence).
Effect estimates. We updated an existing systematic review to identify a range of liver stiffness cutoffs (8.4À18.2 kPa) corresponding to optimal sensitivity and specificity for diagnosis of cirrhosis in adults with HBV. From this, we identified a narrow range of liver stiffness cutoffs, 11.0 (±1) kPa, which corresponded to the most commonly observed value in included studies (17 studies, 4864 patients).
39,57,65À79 Supplementary Table 3 describes the characteristics of these included studies, Supplementary  Figures 3A and B report the sensitivity and specificity of this cutoff. The performance of this cutoff in low-and highrisk populations is shown in Table 9 . In an illustrative lowrisk population (5% prevalence of cirrhosis), for example, patients with HBV detected during routine screening with low HBV viral load, using a cutoff of !11.0 (±1) kPa may misclassify 0.9% patients as not having cirrhosis (FN), and 16.1% patients as having cirrhosis (FP). In an illustrative high-risk population (30% prevalence of cirrhosis), for example, HBV patients with obesity, diabetes, excessive alcohol use, or co-infection with HIV or HCV, using a cutoff of !11.0 (±1) kPa may misclassify 5.7% patients as not having cirrhosis (FN) and 11.9% patients as having cirrhosis (FP).
Quality of evidence. Similar to studies related to VCTE in HCV management, the evidence supporting the use of this cutoff was derived from cross-sectional diagnostic accuracy studies. FP and FN rates were used as surrogates for presumed patient-important downstream consequences, and cutoffs were largely obtained from post-hoc analysis corresponding to AUROC, and selective cutoff of !11.0 (±1) kPa was chosen as being most representative. For these reasons, evidence was rated down for imprecision and inconsistency. There was no evidence of serious risk of bias or serious imprecision, and no evidence of publication bias a High heterogeneity, selective inclusion of studies corresponding to cutoff of 11.0 (±1) kPa. b Surrogate patient-important outcomes (FP, FN are surrogates for presumed downstream consequences on patient-important outcomes), no predetermined liver stiffness cutoff, which was determined post-hoc in individual studies, corresponding to AUROC.
was observed. Therefore, using the GRADE approach, the quality of evidence supporting the use of VCTE-defined liver stiffness of !11.0 (±1) kPa for diagnosis of cirrhosis in adults with HBV was rated as low quality. Discussion. Liver stiffness threshold corresponding to cirrhosis seems to vary across the diseases, which could be truly related to differences in underlying disease processes, or may be an artifact of limited prospective research using predefined liver stiffness thresholds to define cirrhosis. While HCC surveillance is required for the majority of patients with HBV regardless of cirrhosis status, the diagnosis of compensated cirrhosis may be useful in identifying patients for antiviral therapy who would do not meet other criteria for receipt of therapy. A priori, the maximal tolerable FN rate accepted by the Technical Review and Guideline Content Expert Panel was 5%À10%, that is, the test threshold would be acceptable if <10% of patients are misclassified as not having cirrhosis. With a cutoff of !11.0 (±1) kPa, we estimated that >80% of patients would be able to avoid liver biopsy with correct classification of either having or not having cirrhosis. Approximately 1% and 5% of low-and high-risk patients, respectively, may be falsely reassured (of not having cirrhosis) and be ineligible to receive antiviral therapy, which can decrease risk of decompensation below the predefined maximal tolerable FN rate of 10%; hypothetically, in a setting where the prevalence of cirrhosis in HBV patients is >50%, the threshold FN rate of 10% would be exceeded. In contrast, this threshold carries an FP rate of 16% and 12% for low-and high-risk patients, respectively, wherein these patients without cirrhosis may be falsely diagnosed as having cirrhosis; receive unnecessary tests and treatment (HBV-related therapy, if there are no other indications for treatment); have anxiety, testing-and treatment-related complications; and lead to excessive burden on resource utilization. Due to the convenience of a noninvasive test, serial testing on a periodic basis may improve the classification of patients with HBV. Liver biopsy may be needed in case there is discrepancy between physician gestalt (based on clinical scenario, imaging such as computed tomography or ultrasound and biochemical markers) and VCTE findings.
Question 6. In adults with NAFLD, is the overall diagnostic performance of VCTE (M-mode) superior to other noninvasive markers of liver fibrosis (APRI, FIB-4) for detection of cirrhosis?
Key message. In adults with NAFLD, VCTE (M-mode) has superior sensitivity and specificity, and lower FP and FN rates, suggesting superior diagnostic performance, as compared to APRI and FIB-4 for detection of cirrhosis.
(Very low quality of evidence).
Effect estimates
We updated an existing well-conducted systematic review on the diagnostic performance of noninvasive tests in patients with CLDs, and identified 11 studies on 1266 patients with NAFLD, which reported on the diagnostic performance of VCTE for detection of cirrhosis using liver biopsy as a reference standard (Supplementary  Table 4) . 48,80À89 In these studies, the liver stiffness cutoff corresponding to AUROC ranged from 10.3 to 22.3 kPa, and the corresponding summary sensitivity and specificity for detection of cirrhosis across this range of cutoffs was 0.90 (95% CI, 0.82À0.95) and 0.87 (95% CI, 0.85À0.89), respectively (Supplementary Figure 4A and B) . VCTE was compared with performance of FIB-4 and APRI for detection of cirrhosis in NAFLD, derived from another recent systematic review. 90 This is summarized in Tables 10 and 11 . Based on this, VCTE classified more patients correctly compared with APRI and FIB-4, with higher rates of TP and TN and lower rates of FP and FN, although these estimates were imprecise in worst-performance scenarios.
Quality of evidence. Studies on diagnostic performance of VCTE in NAFLD were at high risk of bias due to analysis of only patients with successful VCTE, and not an intention-to-diagnose analysis. Unsuccessful or unreliable liver stiffness measurement is high in patients with obesity, in particular those with central adiposity, a population at high-risk for NAFLD. Additionally, several studies on performance of VCTE in patients with suspected NAFLD either excluded obese patients (body mass index !30 kg/m 2 ), or performed only per-protocol diagnosis (excluding patients with unreliable VCTE) contributing to artificially high sensitivity and specificity. Similar to other VCTE studies in HCV and HBV, evidence was rated down for inconsistency. In the comparison of VCTE vs APRI, there was evidence of serious imprecision for both ruling in and ruling out cirrhosis, whereas in the comparison of VCTE vs FIB-4, there was evidence of serious imprecision for ruling in, but not ruling out, cirrhosis in worst-performance scenarios (using lower limit of 95% CI for diagnostic accuracy of VCTE and upper limit of 95% CI of APRI or FIB-4). Therefore, using the GRADE approach for diagnostic accuracy studies, the quality of evidence supporting the use of VCTE over APRI or FIB-4 for detection of cirrhosis was rated as very low quality.
Discussion. NAFLD is estimated to affect about 24% of Americans, and a small proportion of them can progress to cirrhosis. 8, 91 Through a systematic review, we identified that although VCTE had superior diagnostic performance compared with APRI and FIB-4, there were limitations in the literature, particularly high rates of unsuccessful or unreliable VCTE readings with M-probe in obese patients and selection bias in studies, excluding obese patients at high risk for NAFLD. In a prospective study, XL probe was able to overcome some limitations of M-probe, with higher rates of successful (95% vs 81%) and reliable (90% vs 74%) liver stiffness measurement. 86 However, even with the XL probe, reliable liver stiffness measurements could be obtained in only 65% of obese patients. In another study of 169 patients with NAFLD, body mass index and waist circumference negatively impacted the diagnostic accuracy of VCTE; in their intention-to-diagnose analysis, the AUROC for diagnosis of advanced fibrosis or cirrhosis with VCTE was 0.65. 92 MRE also has superior diagnostic performance compared with VCTE to detect fibrosis in patients with NAFLD. 81 With several novel pharmacologic therapies in development for patients with NAFLD, significant advances are required in noninvasive assessment of fibrosis in these patients to identify treatment candidates and assess response to therapy. 
We updated an existing systematic review to identify a range of liver stiffness cutoffs (7.2À34.9 kPa) corresponding to optimal sensitivity and specificity for diagnosis of cirrhosis in adults with NAFLD based on 14 studies (834 patients). 93 From this, we identified a narrow range of liver stiffness cutoffs, !12.5 (±1) kPa, which corresponded to the most commonly observed value in included studies (7 studies, 330 patients).
94À100 Supplementary Table 5 describes the characteristics of these included studies, and Supplementary Figures 5A and B report the sensitivity and specificity of this cutoff. The performance of this cutoff in low-and high-risk populations is shown in Table 12 . In an illustrative low-risk population (5% prevalence of cirrhosis), for example, patients with chronic excessive alcohol use without any other high-risk factors, using a cutoff of !12.5 (±1) kPa may misclassify 0.2% patients as not having cirrhosis (FN), and 27.5% patients as having cirrhosis (FP). In an illustrative high-risk population (30% prevalence of cirrhosis), for example, patients with alcoholic liver disease with advanced age, obesity, diabetes, and co-infection with HIV/HBV/HCV, using a cutoff of !12.5 (±1) kPa may misclassify 1.5% as not having cirrhosis (FN), and 20.3% patients as having cirrhosis (FP).
Quality of evidence. Similar to prior questions pertaining to VCTE cutoffs for diagnosis of cirrhosis in patients with HCV, the overall body of evidence was rated down for indirectness and inconsistency. Therefore, using the GRADE approach for using diagnostic accuracy studies for patient management, the quality of evidence supporting the use of VCTE-defined liver stiffness of !12.5 (±1) kPa for diagnosis of cirrhosis in adults with chronic alcoholic liver disease was rated as low quality. Discussion. Nonproprietary, serum-based fibrosis markers like APRI and FIB-4 have limited utility in diagnosing cirrhosis in patients with chronic alcoholic liver disease. The number of studies is small, and among these, the performance of these markers was poor. Even for VCTE, timing of assessment of liver stiffness is very important-in the presence of acute alcoholic hepatitis, inflammation would increase liver stiffness and a false elevation in VCTE readings. For patients who have been treated for alcoholic hepatitis or have had a sustained period of sobriety with resulting reduction in inflammation, noninvasive assessment of cirrhosis would be helpful in counseling patients and facilitating appropriate cirrhosis supportive care. A priori, the maximal tolerable FN rate accepted by the Technical Review and Guideline Content Expert Panel was 5%À10%, that is, the test threshold would be acceptable if <10% of patients are misclassified as not having cirrhosis. With a cutoff of !12.5 (±1) kPa, we estimated that >70% of asymptomatic patients would be able to avoid liver biopsy with correct classification of either having or not having cirrhosis. Less than 2% of patients with cirrhosis, in both low-and high-risk populations, may be falsely reassured (of not having cirrhosis), and may not receive supportive cirrhosis care. Around 20%À30% of patients without cirrhosis, in both low-and high-risk populations, may be falsely diagnosed as having cirrhosis and receive unnecessary tests (like surveillance for HCC), and have anxiety and testing-related complications, and lead to excessive burden on resource utilization. In the absence of effective directed therapy against alcoholic liver disease, the detection of cirrhosis would not necessarily impact treatment decisions. a High heterogeneity, selective inclusion of studies corresponding to cutoff of 12.5 (±1) kPa. b Surrogate patient-important outcomes (FP, FN are surrogates for presumed downstream consequences on patient-important outcomes), no predetermined liver stiffness cutoff, which was determined post-hoc in individual studies, corresponding to AUROC.
optimal sensitivity and specificity to detect high-risk EVs, we identified a narrow range of liver stiffness cutoffs, 19.5 (±2) kPa, which was the most commonly observed value to rule out high-risk EVs (8 studies, 964 patients), 101À108 and similar to cutoffs identified in the recent Baveno VI consensus conference. 109 Supplementary Table 6 describes the characteristics of these included studies, and Supplementary Figures 6A and B report the sensitivity and specificity of this cutoff. The performance of this cutoff in low-and high-risk populations is shown in Table 13 . In an illustrative low-risk population (5% prevalence of high-risk EVs), for example, patients with newly diagnosed compensated cirrhosis based on imaging (liver nodularity on computed tomography, coarse echotexture on ultrasound, or based on VCTE), with platelet count >150,000/mL, using a cutoff of 19.5 (±2) kPa may misclassify 0.6% patients as not having high-risk EVs (FN), and 41.8% patients as having high-risk EVs (FP). In an illustrative high-risk population (20% prevalence of high-risk EVs), for example, patients with known compensated cirrhosis with platelet count <150,000/mL, using this cutoff may misclassify 2.2% patients as not having high-risk EVs (FN) and 35.2% patients as having high-risk EVs (FP).
Quality of evidence. The observed prevalence of highrisk EVs was much higher in included studies, which included the entire spectrum of patients with CLDs (including patients with decompensated cirrhosis) compared with values used as illustrative examples (restricted to patients with compensated cirrhosis). Due to use of FP and FN as surrogates for presumed downstream consequences, differences in patient population, post-hoc ascertainment of cutoff, selective use of studies (with reported a cutoff of 19.5 kPa), and considerable heterogeneity in estimates, evidence was rated down for imprecision and indirectness. Therefore, using the GRADE approach, the quality of evidence supporting the use of VCTE-defined liver stiffness of 19.5 (±2) kPa to rule out high-risk EVs in adults with compensated cirrhosis was rated as low quality. Discussion. Current American Association for the Study of Liver Diseases guidelines recommend upper endoscopy in all patients with a new diagnosis of cirrhosis to evaluate for the presence of gastroesophageal varices. 110 While the risk of variceal bleeding is very low in patients with no or small varices, the risk increases significantly in patients with highrisk EVs, such that intervention (primary prophylaxis with nonselective b-blockers) is recommended in these patients. With this knowledge, triaging patients at low risk of harboring high-risk EVs through noninvasive liver stiffness measurement is very appealing, especially as the number of patients diagnosed with cirrhosis increases with rising prevalence of NAFLD, new diagnoses of HCV, and increasing uptake of VCTE to assess liver stiffness and classify patients as having cirrhosis or not. However, health care providers and patients need to be aware of test performance, and be comfortable with potential FN and FP rates with attending downstream consequences. A priori, the maximal tolerable FN rate accepted by the Technical Review and Guideline Content Expert Panel was 1%À5%, that is, the test threshold would be acceptable if <5% of patients are misclassified as not having high-risk EVs. With a cutoff of 19.5 (±2) kPa, we estimate that approximately 55% of low-risk patients and 45% of high-risk patients without high-risk EVs may be able to avoid invasive routine testing for high-risk EVs. With this cutoff, <1% of low-risk and <3% of high-risk patients with compensated cirrhosis may be falsely reassured (of not having high-risk EVs), leading to delayed diagnosis and increasing risk of variceal bleeding and associated morbidity and mortality; hypothetically, in a setting where the prevalence of high-risk EVs in patients with compensated cirrhosis is >45%, the maximal tolerable FN rate of 5% would be exceeded. Because VCTE is being proposed as a triage test (to minimize use of an invasive test like upper endoscopy) and not as a test-replacement strategy to esophagogastroduodenoscopy (EGD), patients with liver stiffness >19.5 kPa (both TP and FP) would undergo a confirmatory upper endoscopy to verify diagnosis of high-risk EVs. Therefore, a high FP rate of approximately 40% does not add any additional patient or provider burden or anxiety because routine EGD would have been recommended even if VCTE were not performed. It is important to note that these observations do not apply to patients with decompensated cirrhosis or known EVs and portal hypertension. It should also be mentioned that because patients with no varices or low-risk EVs progress to high-risk EVs gradually over time, serial VCTE assessment at periodic intervals for change in liver stiffness can improve the triage accuracy.
Question 10. In adults with suspected CLDs undergoing elective nonhepatic surgery, at what VCTE-identified liver stiffness cutoff can we accurately rule out clinically significant portal hypertension (identified here by presence of any EVs), potentially minimizing the risk of portal hypertension-related bleeding, obviating the need for routine invasive testing for portal hypertension?
Key message. In adults with suspected CLDs undergoing elective nonhepatic surgery, we can accurately rule out presence of clinically significant portal hypertension (absence of EVs) with VCTE-defined liver stiffness of 17.0 (±2) kPa with acceptable FN rates. (Low quality of evidence).
Effect estimates. From a range of liver stiffness cutoffs (12.0À27.3 kPa) reported in 17 studies corresponding to optimal sensitivity and specificity to detect any EVs, we identified a narrow range of liver stiffness cutoffs, 17.0 (±2) kPa, which was the most commonly observed value to rule out any EVs (8 studies, 895 patients). 101,106,111À116 Supplementary Table 7 describes the characteristics of these included studies, and Supplementary Figures 7A and B report the sensitivity and specificity of this cutoff. The performance of this cutoff in very-low-, low-, and high-risk populations is shown in Table 14 . In an illustrative verylow-risk population (0.5% prevalence of any EVs), for a High heterogeneity, selective inclusion of studies corresponding to cutoff of 19.5 (±2 kPa). b Surrogate patient-important outcomes (FP, FN are surrogates for presumed downstream consequences on patient-important outcomes); no predetermined liver stiffness cutoff, which was determined post-hoc in individual studies, corresponding to AUROC; observed prevalence of high-risk EVs in studies was much higher than that used in illustrative examples (median, 24.7%; range, 10.3%À37%). Quality of evidence. Similar to the PICO on liver stiffness cutoff for triaging high-risk EVs, the quality of evidence for this question was rated down for indirectness and inconsistency, and the overall evidence supporting the use of VCTE-defined liver stiffness of 17.0 (±2) kPa for triaging patients undergoing elective, extrahepatic surgery to minimize the risk of portal hypertensive bleeding was rated as low quality. Discussion. Preoperative surgical risk stratification is a common consultation for hepatologists and gastroenterologists before elective, extrahepatic surgery. Besides ChildPugh score and Model for End-Stage Liver Disease score (which have been validated in patients with known cirrhosis) and specific surgical risk stratification scores, presence or absence of portal hypertension also influences risk of bleeding and postoperative hepatic decompensation. 117, 118 For patients and surgeons considering these procedures, the ability to rule out clinically significant portal hypertension is an important issue and, currently, upper endoscopy or measurement of the hepatic venous pressure gradient is considered. In this technical review, we identified a VCTE-defined liver stiffness threshold of 17.0 (±2) kPa corresponding to presence or absence of EVs. A priori, the maximal tolerable FN rate accepted by the Technical Review and Guideline Content Expert Panel was 1%À5%, that is, the test threshold would be acceptable if <5% of patients are misclassified as not having EVs before elective surgery. With this cutoff, 0.1% of very-low-and <1% of low-risk patients may be falsely reassured (of not having clinically significant portal hypertension), which can lead to increased risk of portal hypertensive bleeding and hepatic decompensation after elective surgery; in contrast, among high-risk patients (with known compensated cirrhosis), approximately 7% may be falsely reassured of not having clinically significant portal hypertension, which is above the maximal tolerable FN rate of 5% identified by the expert panel. Because VCTE is being proposed as a triage test (to minimize use of an invasive test like upper endoscopy or hepatic venous wedge pressure measurement) and not as a test-replacement strategy to EGD, patients with liver stiffness >17.0 kPa (both TP and FP) would undergo a confirmatory upper endoscopy to verify diagnosis of any EVs before being deemed high-risk candidates. Therefore, a high FP rate of approximately 30%À50% does not necessarily add any additional patient or provider burden or anxiety, because routine EGD would have been recommended even if VCTE were not performed. With such a high FP rate, Child-Pugh score, Model for End-Stage Liver Disease score, and other presurgical risk stratification scores may continue to be used as part of this clinical evaluation.
Question 11. In adults with chronic HCV, is the overall diagnostic performance of MRE superior to VCTE for detection of cirrhosis?
Key message. In adults with HCV, MRE has little to no increased diagnostic accuracy in identifying cirrhosis in patients who truly have cirrhosis over VCTE, but has lower diagnostic accuracy in ruling out cirrhosis in patients who do not have cirrhosis, over VCTE (Very low quality of evidence).
Effect estimates. We did not identify any head-to-head study comparing MRE vs VCTE in adults with HCV. Therefore, we indirectly compared the performance of MRE and VCTE based on well-conducted systematic reviews on the diagnostic performance of MRE and VCTE for assessment of liver fibrosis and cirrhosis in patients with CLDs. 36, 119 In a recent pooled analysis of individual participant data (IPD) on the diagnostic performance of MRE, a cutoff of 4.71 had the highest accuracy for detecting cirrhosis in patients with HCV, with summary sensitivity and specificity of 0.94 (95% CI, 0.87À0.97) and 0.81 (95% CI, 0.61À0.98), respectively. 119 In another study-level systematic review of 36 studies of VCTE in patients with HCV, across a liver stiffness cutoff range from 9.2 to 17.3 kPa, the summary sensitivity and specificity for detection of cirrhosis were 0.89 (95% CI, 0.84À0.92) and 0.91 (95% CI, 0.89À0.93), respectively. 36 The evidence profile is summarized in Table 15 . Based on this, there was little or no difference between MRE and VCTE in classifying patients correctly as having cirrhosis (TP), but MRE was inferior to VCTE in ruling out cirrhosis (TN) in both low-and high-prevalence populations.
Quality of evidence. All included studies were crosssectional diagnostic accuracy studies, required <6 months between performance of diagnostic test and gold standard (liver biopsy) minimizing disease progression bias, and generally of fair quality and not at serious risk of bias (spectrum bias, disease progression bias, partial or differential verification bias, adequate blinding of outcome assessors). Evidence was rated down for indirectness, due to: absence of head-to-head comparisons between MRE and VCTE, and differences in study design for estimating diagnostic performance of MRE (pooled analysis of IPD) and VCTE (study-level meta-analysis). Considerable heterogeneity was observed in pooled sensitivity and specificity, and there was a wide range of "ideal" cutoffs for VCTE (corresponding to AUROC), rather than prespecified cutoffs for detection of cirrhosis, and hence, evidence was rated down for inconsistency. Evidence was also rated down for imprecision in ruling in cirrhosis since VCTE was superior to MRE in the worst-performance scenarios (using lower limit of 95% CI for diagnostic accuracy of MRE, and upper limit of 95% CI of VCTE). Therefore, using the GRADE approach for diagnostic accuracy studies, the overall quality of evidence supporting the use of MRE over VCTE for detection of cirrhosis, was rated as very low quality (very low certainty in the comparative evidence). Discussion. Based on indirect comparisons, MRE had little to no increased diagnostic accuracy over VCTE in correctly identifying patients with HCV who truly have cirrhosis. In contrast, VCTE was superior to MRE in ruling out cirrhosis in these patients, with lower rates of misclassifying noncirrhotic patients as having cirrhosis, although there was low confidence in the comparative estimates. Study-level diagnostic accuracy meta-analysis of aggregate data tend to overestimate diagnostic performance due to spectrum bias, are more likely to have selective reporting bias, and are limited in ability to identify an optimal diagnostic threshold. 120 In contrast, pooled analysis of IPD is a more robust study design, overcoming several of these limitations and, traditionally, the diagnostic performance in IPD analysis is inferior to that observed in studylevel meta-analyses; this may have biased estimates in favor of VCTE. It is important to note that most included studies derived diagnostic accuracy based on the "completer" population, and excluded patients who were unable to successfully undergo diagnostic tests (ie, did not perform intention-to-diagnose analyses). Although failure rate of MRE may be lower than that of VCTE in specific patient populations (eg, obese patients), patient preferences in choosing between MRE and VCTE are not well studied, and can differ-MRE is conducted in a specialist radiology center, whereas VCTE may be performed in the office at point of care; claustrophobia can also be a consideration. Although a formal cost-effectiveness analyses was not performed, it is highly unlikely that MRE would be more costeffective than VCTE in detection of cirrhosis in patients with HCV, given marginal differences in diagnostic accuracy.
Question 12. In adults with NAFLD, is the overall diagnostic performance of MRE superior to VCTE for detection of cirrhosis?
Key message. In adults with NAFLD, MRE has little to no increased diagnostic accuracy in identifying cirrhosis in patients who truly have cirrhosis over VCTE, but has considerably higher diagnostic accuracy in ruling out cirrhosis in patients who do not have cirrhosis, over VCTE (Very low quality of evidence).
Effect estimates. Two head-to-head trials comparing the diagnostic performance of MRE vs VCTE in 246 patients with NAFLD (7.8% with cirrhosis) were identified. 81, 121 On pooling these 2 studies, the summary sensitivity and specificity of MRE for detection of cirrhosis (cutoff, 3.4À6.7 kPa) was 0.84 (95% CI, 0.60À0.97) and 0.89 (95% CI, 0.84À0.93), respectively; the corresponding sensitivity and specificity for VCTE (cutoff, 6.9À14.0 kPa) was 0.83 (95% CI, 0.59À0.96) and 0.72 (95% CI, 0.65À0.78), respectively. The evidence profile is summarized in Table 16 . Based on this, MRE was superior to VCTE in ruling out cirrhosis (TN) and was comparable with VCTE in classifying more patients correctly as having cirrhosis (TP). Using these estimates for MRE, in an illustrative low-risk population ( 5% prevalence of cirrhosis), for example, patients incidentally noted to have fatty liver on imaging with normal or minimally elevated liver enzymes and typically seen in the primary care clinic, MRE may misclassify 0.8% patients as not having cirrhosis (FN) and 10.5% patients as having cirrhosis (FP); the positive predictive value of MRE would be 29%. In an illustrative high-risk population (30% prevalence of cirrhosis), for example, older NAFLD patients with obesity, particularly central adiposity, diabetes, alanine aminotransferase elevated >2Â upper limit of normal, and typically seen in a referral liver clinic, MRE may misclassify 4.8% patients as not having cirrhosis (FN) and 7.7% patients as having cirrhosis (FP).
Quality of evidence. Both included studies were prospective cross-sectional diagnostic accuracy studies, but only analyzed patients who successfully completed VCTE and MRE; given high failure rate of VCTE in obese patients with NAFLD, evidence was deemed to be at risk of bias. Due to considerable differences in identified cutoffs and heterogeneity observed in sensitivity and specificity, evidence was also rated down for inconsistency. Evidence was also rated down for imprecision in ruling in cirrhosis given considerable overlap in diagnostic performance in the bestand worst-performance scenarios of diagnostic tests. Therefore, using the GRADE approach for diagnostic accuracy studies, the overall quality of evidence supporting the use of MRE over VCTE for detection of cirrhosis in patients with NAFLD was rated as very low quality (very low certainty in the comparative evidence). Discussion. Based on head-to-head comparisons, MRE was superior to VCTE in ruling out cirrhosis in adults with NAFLD, but offered little to no increased diagnostic accuracy in detecting cirrhosis. Under conditions optimized to improve diagnostic accuracy (as seen in included studies), MRE has a modest positive predictive value, especially in a low prevalence setting; that is, in a setting with cirrhosis prevalence 5%, only 29% of patients with MRE "positive for cirrhosis" would truly have cirrhosis. This could result in a considerable proportion of patients with positive MRE being classified as having cirrhosis, and potentially cause harm in the form of anxiety and/or subject these patients to invasive testing with liver biopsy. In addition, because the cutoff for identifying cirrhosis with MRE is not well-defined, it can result in site-to-site variability. Unlike HCV, where fibrosis assessment is recommended at diagnosis to guide treatment, there is limited consensus on when fibrosis assessment should be performed in patients suspected of having NAFLD, regardless of modality. For example, current American Gastroenterological Association/ American Association for the Study of Liver Diseases/ American College of Gastroenterology guidelines on NAFLD recommend against liver biopsy in asymptomatic patients with unsuspected hepatic steatosis with normal liver biochemistry; for these patients at very low risk of having cirrhosis, positive predictive value with MRE will be very low, resulting in significant misclassification. 122 To augment diagnostic performance and interpretability of MRE (and minimize rates of FN and FP), a more accurate risk stratification scheme to identify patients at high risk of progression to liver-related complications is warranted. Currently, treatment options that can favorably modify the natural history in patients with NAFLD are very limited; as effective therapies become available, thresholds for acceptable misclassification of cirrhosis with noninvasive imaging modalities may change.
Key Aspects in Interpreting the Technical Review
This technical review provides a somewhat different approach to analyzing VCTE performance in clinical practice when compared with narrative reviews in the field so far. Firstly, we do not provide a table that aligns the kPa values with fibrosis stage (F0 to F4). The reason is that by doing so, we would ignore that a specific kPa value/fibrosis stage pair is associated with defined FN and FP rates, and although lowering kPa thresholds decreases the FN rate, it will invariably increase the FP rates. Rather, clinical goals should guide the threshold-setting procedure.
Secondly, we provide thresholds for maximal tolerable FN rates in different patient-management scenarios, and these were based on predefined, best consensus judgment of clinical content experts. However, acceptable thresholds for maximal tolerable FN rates can vary from practitioner to practitioner when discussing diagnostic approaches with patients (some may have lower tolerance of FNs and others higher tolerance), depending on patients' values and preferences and subtle variations in clinical scenarios. Therefore, eliciting patient's values and preferences and tolerance for test inaccuracies is important and requires appropriate contextualization depending on clinical practice to enable best utilization of observations in this technical review.
Lastly, by rating our confidence in the evidence of downstream clinical consequences of true test positives and negatives, but also the potentially detriment of FNs (missing a diagnosis) and FPs (overdiagnosing), our goal was to increase transparency in the process and enable clinicians to provide optimal shared decision making.
Limitations of Current Evidence and Future Directions
This review of the literature for VCTE in patients with liver disease revealed a number of limitations. First, studies used a wide range of cutoffs for VCTE to define fibrosis stages in CLDs, mostly identified post-hoc corresponding to the AUROC, and this variability subsequently impacted the quality of evidence. Future studies need to evaluate the performance of standard predefined cutoffs for the different liver diseases. Second, the strength of the VCTE literature is in HCV but is generally limited to the initial assessment. Many patients with advanced fibrosis and cirrhosis have been or will soon be cured of their HCV, and there is hope that many will see improvement in their fibrosis in time. Their long-term care is currently expected to include surveillance for the complications of portal hypertension and liver cancer for many years. Studies are needed to establish ongoing assessment and determine whether fibrosis (or early cirrhosis) has regressed to the point where ongoing surveillance will no longer be required. However, this will likely require correlation with liver biopsies, as the decrease over time in kPa values alone may, or may not, be related to fibrosis regression, as other factors, such as degree of inflammation or fatty infiltration, may influence liver stiffness. Third, there is major dearth of high-quality evidence in patients with NAFLD. As more patients present for evaluation (including asymptomatic patients incidentally noted to have hepatic steatosis) and therapies are developed for the treatment of NAFLD, clinicians will require effective risk stratification and diagnostic tools to identify patients with progressive fibrosis at risk for complications. Fourth, due to limited data, prospective evaluation of the utility of VCTE as a triage test to evaluate for absence of high-risk EVs and ruling our clinically significant portal hypertension before elective surgery is warranted. Finally, although a variety of noninvasive imaging-based fibrosis assessment modalities have been developed, our review focused on VCTE and MRE only; a detailed synthesis of the performance and utility of other noninvasive imaging modalities, such as acoustic radiation force pulse imaging or shear wave elastography, in CLDs, particularly NAFLD, is warranted.
